Epidemiological studies and basic research suggest a protective effect of long-chain omega-3 polyunsaturated fatty acids, antioxidants and B vitamins against brain aging. However, most randomized controlled trial (RCTs) with nutritional supplements have yielded disappointing effects on cognition so far. This paper suggests some original directions for future research to better support a role of nutrition in brain aging. The role of other nutrients such as docosapentaenoic acid and fat-soluble vitamins D and K should be investigated. A more holistic approach of nutrition is necessary, encompassing potential synergies between nutrients as found in a balanced diet. Potential beneficiaries of a nutritional supplementation should be better targeted, according to their dietary, cognitive and maybe genetic characteristics. Innovative RCTs should be implemented to assess the impact of nutrition for the prevention or treatment of cognitive decline in older persons, using intermediate biomarkers of disease progression and mechanisms of action of nutrients as outcomes.
INTRODUCTION
In accordance with the results of basic research, epidemiological studies suggest a protective effect of several classes of nutrients against cognitive decline and risk of dementia, 1,2 including principally long-chain omega-3 polyunsaturated fatty acids (n-3 PUFA), 3, 4 vitamins C and E, 5 carotenoids, 6 polyphenols 7 and B vitamins, 8 although some discordant data exist as well. Many underlying mechanisms can be evoked to support biological plausibility of a protective effect of these nutrients against brain aging: role in brain composition and function, 9 hippocampal neurogenesis, 10 limitation of accumulation of the beta-amyloid peptide, 11, 12 decreased oxidative stress and inflammation, 13 decreased homocysteine concentration 8 and vascular effects. 14 However, most well-conducted randomized controlled trials (RCTs) with nutritional supplements have yielded disappointing effects on cognition so far (for reviews, see Wald et al., 15 Mazereeuw et al. 16 and Dangour et al. 17 ). As written by Dangour et al. 17 regarding n-3 PUFA but easily transferable to other nutrients, whether discrepancies between epidemiological and intervention studies 'reflect a real absence of benefit on cognitive function from (nutritional) supplementation, or whether they reflect intrinsic limitations in the design of published studies remains open to question'. The aim of this paper was to suggest new areas of research to better support a role of nutrition in brain aging. Two aspects are developed: nutritional exposure, concerning the investigation of new nutrients and a more holistic approach of the diet, and innovative RCTs with nutritional supplements, regarding their inclusion criteria and outcomes in relation with cognition.
INVESTIGATING NEW NUTRIENTS
There is convincing evidence that fats are a major class of nutrients for brain development, structure and functioning. 9 However, previous studies have neglected some fatty acids or fat-soluble vitamins that could have an important role in the brain. Docosapentaenoic acid (DPA) Actually, the term DPA refers to two different fatty acids: one in the omega3 series C22:5n-3, situated between eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the desaturation and elongation chain of alpha-linolenic acid, and another one in the omega6 series C22:5n-6 resulting from elongation, desaturation and beta-oxidation of arachidonic acid. As EPA and DHA, n-3 DPA is mainly found in fatty fish and could contribute to the apparently protective effect of fish consumption against cognitive decline. The metabolism and biological functions of DPA are still poorly understood. Supplementation with pure n-3 DPA induced a significant rise in the proportions of EPA and DHA in plasma triacylglycerides, suggesting that DPA may act as a reservoir of the major long-chain n-3 PUFA in humans. 18 In healthy humans under their spontaneous diet, n-3 DPA is found in non-negligible amounts in cerebrospinal fluid (CSF) and positively correlated with total plasma n-3 PUFA. 19 N-6 DPA in erythrocytes was higher in 48 older individuals with mild cognitive impairment (MCI) than in 27 healthy controls in a cross-sectional analysis carried at baseline of an RCT. 20 Higher n-6 DPA also correlated with poorer mental health and less satisfaction with life, while lower n-3 DPA was associated with a higher frequency of self-reported body pain. Data from this small study with multiple statistical testing should be reproduced in larger, longitudinal studies before drawing firm conclusions. In the Three-City cohort study, plasma n-3 DPA was not associated with risk of incident dementia, and n-6 DPA was not available. 21 Vitamin D Beyond its role in bone health, the multiple biological functions of vitamin D are raising increasing interest. 22 In humans, vitamin D Meta-analyses of case-control studies showed that patients with Alzheimer's disease (AD) had lower serum vitamin D concentrations than controls, 23 with borderline significance after adjusting for age. 24 Longitudinal studies are scarce. Participants in the InCHIANTI cohort study who were severely vitamin D deficient according to their serum 25-hydroxy-vitamin D levels (o25 nmol/l) had a significantly increased risk of cognitive decline over 6 years. 25 However, this association was not reproduced in another longitudinal study. 26 Several RCTs assessing the impact of vitamin D on cognition, either as primary or a secondary outcome, are in progress (clinicaltrials.gov). In the Women's Health Initiative, supplementation with 400 IU/day of vitamin D, along with calcium, did not result in decreased risk of dementia or cognitive decline, compared with the placebo group over a mean follow-up of 8 years. 27 If ongoing RCTs yield more positive results with higher doses of vitamin D, improvement of cognitive function would be a beneficial side-effect of systematic vitamin D supplementation in deficient individuals.
Vitamin K A growing body of evidence supports a role for vitamin K in brain and cognition. 28 Several vitamin K-dependent proteins contribute to brain function, notably Gas6 which is expressed in the hippocampus of adult rat and contributes to survival of neurons and microglia. Moreover, vitamin K is involved in sphingolipid metabolism. 28 Dietary vitamin K is provided by vegetables, whose consumption is inversely associated with cognitive decline and risk of dementia. 29 Data on the relationship between vitamin K status and cognition in humans are lacking. A single crosssectional epidemiological study showed a specific relationship between high serum vitamin K (phylloquinone) concentrations and better performances in verbal episodic memory in 320 healthy older adults. 30 These data need to be confirmed in longitudinal studies using serum phylloquinone as a biomarker of vitamin K status.
FROM A SINGLE-NUTRIENT APPROACH TO DIETARY PATTERNS
Most previous epidemiological studies and RCTs have focused on single nutrients, ignoring their potential synergistic effects when they are provided in optimal quantities and proportions as in a balanced diet. Considering dietary patterns may lead to a more holistic approach of the diet. 31 Diets rich in fruits, vegetables, vegetable oils, legumes, cereals and fish provide folate, vitamins C and E, carotenoids, polyphenols and long-chain n-3 PUFA along with a low glycemic index that contribute to lower inflammation, oxidative stress and homocysteine concentration, improve vascular status and insulin sensitivity and maintain brain structure and functioning. 32 Moreover, some combinations of nutrients may have synergistic effects that will reinforce their individual properties. For example, antioxidant nutrients can protect long-chain n-3 PUFA from peroxidation to which they are particularly susceptible because of their multiple double bonds.
Folate and n-3 PUFA In the Three-City cohort study, we observed that regular fish consumption was not protective against risk of dementia if not accompanied by regular intake of fruits and vegetables. 33 Accordingly, a placebo-controlled RCT showed that response to n-3 PUFA supplementation (2 g EPA and 1 g DHA per day) for 6 weeks was enhanced in individuals who reported being high consumers of dark-green vegetables. 34 These vegetables are good dietary sources of folate and lutein, a carotenoid, suggesting a potential interaction between these nutrients and the absorption or bioavailability of n-3 PUFA. However, an another RCT, ancillary study of the SU.FOL.OM3 trial providing B vitamins (including 560 μg/d folate), EPA (400 mg/d) and DHA (200 mg/d) in individuals with a history of cardiovascular disease did not evidence any improvement of cognitive function after 4 years, except maybe in some specific subgroups. 35 Healthy diets In observational studies, several models of healthy diets combining multiple classes of nutrients have been found to be associated with lower cognitive decline and risk of dementia, the most widely studied being the Mediterranean diet. 2, 31 A recent meta-analysis evidenced that higher adherence to a Mediterranean-type diet is associated with a reduced risk of developing MCI and AD. 36 However, the construct of 'Mediterranean diet' may actually encompass very different food and nutrient intakes, depending on the population and geographical area, as most scoring instruments developed to assess adherence to this dietary model are based on sample-specific medians.
Very few RCTs have assessed the impact of shifting to a global healthier diet on cognition. In the PREDIMED-NAVARRA study, participants at high vascular risk randomized to receive intensive advice to adopt a Mediterranean diet enriched with virgin olive oil or nuts scored significantly better than the low-fat control group on the Mini Mental Status Examination (MMSE), a global test of cognitive performance, and the Clock Drawing Test, assessing a wide range of high-level cognitive abilities including executive functions, after 6½-year follow-up. 37 However, cognition was not measured at baseline, and the impact of the diets on cognitive decline could thus not be assessed. The Exercise and Nutritional Interventions for Cardiovascular Health RCT was designed to examine the effects of the Dietary Approach to Stop Hypertension, alone or in combination with weight management through physical exercise and calorie restriction, on blood pressure in overweight adults with high blood pressure. The Dietary Approach to Stop Hypertension diet was associated with a significantly improved psychomotor speed relative to controls. 38 Supplements with multiple nutrients RCTs with supplements containing various combinations of nutrients trying to reproduce healthy diets can be used to provide a proof of concept of their global impact on cognition. A systematic review of 10 RCTs with multivitamins provided weak evidence of improvement of some cognitive abilities, especially immediate free recall. 39 However, the few available studies were very heterogeneous regarding inclusion criteria, multivitamin constituents and cognitive outcomes. More convincingly, the Souvenir-II placebo-controlled RCT showed that a 24-week supplementation with Souvenaid was able to improve memory in drug-naive patients with mild AD, that is, an MMSE score ⩾ 20. 40 Souvenaid provides EPA, DHA, B vitamins, antioxidants (vitamins C and E, selenium), choline and uridine monophosphate, a specific combination intended to improve synaptic dysfunction in AD. These trials need to be replicated in populations with various degrees of cognitive impairment to identify the most responsive individuals in whom a supplementation could be recommended.
BETTER TARGETING POTENTIAL BENEFICIARIES OF NUTRITIONAL INTERVENTIONS
RCTs with nutritional supplements have been carried for the primary or secondary prevention of dementia or for treatment of patients with mild-to-moderate AD (MMSE range 10-26). Some may have failed to show any significant impact on cognition, either because they have included healthy participants who did not decline during the few months of the trial 41 or, conversely, individuals with AD whose disease was probably too severe to expect a significant effect from nutrition. [42] [43] [44] Few studies have specifically targeted the MCI stage. 45, 46 Identifying individuals who are the most susceptible to benefit from a nutritional supplementation is therefore of upmost importance. 47 Cognitive criteria and biomarkers of disease progression In its strict definition, primary prevention takes place before the development of the disease, that is, before any sign of neurodegeneration in the case of AD. Healthy diets in early life could contribute to develop brain reserve. 48 However, the impact of interventions targeting this population on late life cognitive performance is obviously impossible to evidence. Thus primary and secondary prevention of dementia cannot be disentangled. However, cognitive decline is a relatively late event in the course of the disease, and it has been estimated that beta-amyloid, the hallmark of AD, accumulates sharply for about 15 years in the brain before reaching a plateau when the first clinical signs emerge. 49 This 15-year interval would represent a large window for secondary prevention, especially with nutritional interventions. In the absence of specific impairment on most neuropsychological tests at this stage, biomarkers of disease progression could help to identify the best window of opportunity for RCTs with nutritional supplements. These biomarkers include brain atrophy as measured by magnetic resonance imaging, impaired brain glucose metabolism and imaging of beta-amyloid accumulation with positron emission tomography and measurements of betaamyloid and phosphorylated tau in CSF. 50 However, in our present state of knowledge these should be considered only as research criteria and not used for screening individuals at high risk of dementia.
Nutritional criteria Contrarily to RCTs with drugs, participants in nutritional interventions do not have a null basal level of the nutrient to be evaluated before any supplementation. There is a large day-to-day (intraindividual) variability, especially for nutrients brought by foods that are not consumed on a daily basis such as fish, the main dietary provider of EPA and DHA. In addition, there is a large interindividual variability, depending on dietary habits. Both sources of variability decrease the power of the study by inflating confidence intervals and may hamper its external validity. Providing individuals who already meet their dietary requirements with additional quantities of nutrients is probably useless and may even be harmful when upper tolerable intake levels are surpassed. 51 Inclusion criteria should consider nutritional criteria such as low intake of EPA or DHA [52] [53] [54] or low blood levels of long-chain n-3 PUFA. 4 Global malnutrition assessed on generic tools such as the Mini-Nutritional Assessment could also help targeting older individuals who could benefit from a nutritional supplementation. 55 Genetic characteristics Gene × diet interactions on cognition are still poorly understood. The epsilon 4 allele of the Apolipoprotein E (APOE4) gene, the main genetic risk factor for AD, is associated with poorer blood response to supplementation with n-3 PUFA 56 or fish intake. 57 Moreover, some epidemiological studies and RCTs have evidenced that APOE4 carriers had no benefit of n-3 PUFA supplementation or fish consumption on cognition. 58 Other genetic risk factors of AD involved in lipid metabolism could also interact with dietary n-3 PUFA. 59 Further research is needed to better identify these interactions before considering genetic characteristics as inclusion criteria in RCTs with nutritional supplements. In the present state of knowledge, population screening of individuals based on their genotype would be unethical, but it will probably emerge in the future with the perspective of a 'personalized nutrition'.
DESIGNING INNOVATIVE INTERVENTION STUDIES
Inability of most RCTs with nutritional supplements to show any effect on cognitive performance may in part lie in lack of sensitivity of the selected outcomes to change over a relatively short period. Beside traditional criteria based on cognitive and functional decline, biomarkers could contribute to provide evidence of an impact of nutrients and shed new light into their mechanisms of action.
Biomarkers of disease progression Few RCTs with nutritional supplements have used brain or CSF biomarkers of neurodegeneration as outcomes. These biomarkers could be more sensitive and capture early changes in the course of the disease that do not translate yet into improved cognitive performances. In the VITACOG RCT, the rate of brain atrophy over 24 months measured by magnetic resonance imaging as primary outcome was significantly reduced by 30% by supplementation with B vitamins compared with placebo in 168 elderly subjects with MCI. 45 Conversely, there was no effect of DHA supplementation on brain volume change over 18 months in the subsample of 102 participants with AD who had repeated magnetic resonance imaging examination in the Alzheimer's Disease Cooperative Study RCT. 53 However, that subsample size was probably too small to achieve sufficient power.
Forty-nine older adults (20 healthy and 29 with amnestic MCI (aMCI)) were randomized to follow a HIGH or LOW diet for 4 weeks. 46 The HIGH diet was high in fat, especially saturated fat, and with a high glycemic index. Conversely, the LOW diet was low in fat, especially saturated fat, and had a low glycemic index. In aMCI patients, the LOW diet increased beta42-amyloid concentrations in CSF but had the opposite effect in healthy adults, suggesting different mechanisms of action on the accumulation or clearance of beta-amyloid depending on the stage of the disease. The apolipoprotein E concentration in CSF was increased by the LOW diet and decreased by the HIGH diet. These changes in disease biomarkers were accompanied by improvement in delayed visual recall assessed by the Brief Visuospatial Memory Test with the LOW diet.
Biomarkers of mechanism of action Many biomarkers of putative mechanisms of action of nutrients can also be proposed, preferably as secondary outcomes, in RCTs. These include principally measures of inflammation, 60 oxidative stress assessed by isoprostanes in CSF, 44, 46 homocysteine 61 and markers of insulin resistance. 46 In the LOW/HIGH RCT cited above, 46 the CSF insulin concentration increased with the LOW diet in aMCI patients, whereas the HIGH diet lowered the CSF insulin concentration for healthy adults. As an interpretation of these findings, the authors suggest that restoration of normal insulin concentration and activity in central nervous system may have beneficial effects, such as protection against synaptotoxicity of beta-amyloid oligomers. The peripheral metabolic profile of participants was also changed as the HIGH diet increased and the LOW diet decreased plasma lipids and insulin concentration in both groups, indicating improved insulin sensitivity with the LOW diet. The LOW diet also had a favourable impact on oxidative stress with reduced F2-isoprostane concentrations in CSF. 46 However, some inconsistent results may arise from cognitive and biomarker outcomes. For instance, most RCTs with B vitamins have shown a non-significant impact on cognition 15 despite a strong homocysteine-lowering effect. Paradoxically, supplementation with a cocktail of antioxidant nutrients was able to decrease oxidative stress as shown by CSF isoprostanes but increased cognitive decline. 44 The considerable development of omics technologies will give new insight into the potential metabolic pathways involved in the link between nutrition and brain functioning and provide new integrative biomarkers that will help understand their effects. For example, lipidomic profiling recently identified a set of 10 lipids in plasma that predicted short-term conversion to aMCI or AD with a very high accuracy in healthy elderly persons. 62 These phospholipids have essential structural and functional roles in cell membranes, suggesting that their peripheral blood levels could be an early correlate of neurodegeneration in AD. Moreover, this specific lipid profile could be used as inclusion criteria in more efficient RCTs of nutritional interventions with lipids for the prevention of cognitive decline.
CONCLUSION
Despite the disappointing results of nutritional interventions on cognition so far, there is considerable room for improvement and more evidence-based knowledge on the link between nutrition and cognitive decline in older persons. Trials with nutritional supplements should learn from RCTs with drugs regarding biomarkers of disease progression for inclusion criteria and outcomes. Progress in genetics and omics technologies will also offer new opportunities for research in this field.
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